Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SSTR5 | P35346 | 17/20 | 0.76 |
| ▸ | SSTR2 | P30874 | 16/20 | 0.76 |
| ▸ | SSTR3 | P32745 | 9/20 | 0.76 |
| ▸ | SSTR1 | P30872 | 9/20 | 0.76 |
| ▸ | SSTR4 | P31391 | 8/20 | 0.76 |
| ▸ | IL23R | Q5VWK5 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Depreotide SCHEMBL29399302 | 0.97 | SSTR5 (0.79) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Depreotide SCHEMBL456503 | 0.97 | SSTR5 (0.79) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Depreotide SCHEMBL29392879 | 0.85 | SSTR5 (0.62) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL24108700 | 0.81 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| SCHEMBL22214904 | 0.81 | SSTR5 (1.00) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Vapreotide SCHEMBL5200070 | 0.71 | SSTR2 (0.78) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Seglitide SCHEMBL25456114 | 0.71 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Seglitide SCHEMBL151244 | 0.71 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Seglitide SCHEMBL29691513 | 0.71 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR1SSTR4 | |
| Seglitide SCHEMBL29392970 | 0.71 | SSTR5 (0.56) | SSTR5SSTR2SSTR3SSTR1SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | claimed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | claimed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | claimed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | claimed |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2026-05-12 | — | — | US | disclosed |
| US-20250375388-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | UNIV MICHIGAN REGENTS (US) | 2025-12-11 | — | — | US | disclosed |
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2025-07-03 | — | — | US | disclosed |
| US-12257352-B2 | Compositions and methods for delivery of biomacromolecule agents | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2025-03-25 | — | — | US | disclosed |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-08-22 | — | — | US | disclosed |
| EP-4408480-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2024-08-07 | — | — | EP | disclosed |
| EP-4228657-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2023-08-23 | — | — | EP | disclosed |
| CN-116390764-A | Crystalline polymorphic forms of STING agonist bound to metal ions capable of modulating immune responses | 密歇根大学董事会 | 2023-07-04 | — | — | CN | disclosed |
| WO-2021119439-A1 | COMPOSITIONS AND METHODS FOR SYSTEMIC DELIVERY OF BCL-2 AND BCL-XL ANTAGONISTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-17 | — | — | WO | disclosed |
| EP-3820534-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | The Regents Of The University Of Michigan (US) | 2021-05-19 | — | — | EP | disclosed |
| US-20210106538-A1 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN | 2021-04-15 | — | — | US | disclosed |
| EP-3471778-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | The Regents of The University of Michigan (US) | 2019-04-24 | — | — | EP | disclosed |
| WO-2018156617-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF POLYMER / BIOMACROMOLECULE CONJUGATES | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-30 | — | — | WO | disclosed |
| WO-2017223085-A2 | COMPOSITIONS AND METHODS FOR DELIVERY OF BIOMACROMOLECULE AGENTS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2017-12-28 | — | — | WO | disclosed |
| US-9427483-B2 | Radioisotope trithiol complexes | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2016-08-30 | — | — | US | disclosed |
| US-20150283274-A1 | RADIOISOTOPE TRITHIOL COMPLEXES | THE CURATORS OF THE UNIVERSITY OF MISSOURI (US) | 2015-10-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250213474-A1 | COMPOSITIONS AND METHODS FOR METAL CONTAINING FORMULATIONS CAPABLE OF MODULATING IMMUNE RESPONSE | MYD88, STING1, TLR3 | SSTR5 4568/4885SSTR2 4673/4885SSTR3 4576/4885 |
| US-20150283274-A1 | RADIOISOTOPE TRITHIOL COMPLEXES | ICMT, QTRT1, QPCT | SSTR5 83/4885SSTR2 118/4885SSTR3 37/4885 |
| US-20240277751-A1 | CRYSTALLINE POLYMORPHIC FORMS OF STING AGONISTS ASSOCIATED WITH METAL IONS CAPABLE OF MODULATING AN IMMUNE RESPONSE | STING1, CGAS, IRF3 | SSTR5 2981/4885SSTR2 2547/4885SSTR3 1233/4885 |
| US-12622922-B2 | Compositions and methods for metal containing formulations capable of modulating immune response | STING1, CGAS, TLR3 | SSTR5 3634/4885SSTR2 2182/4885SSTR3 2548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.